REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with MM (multiple myeloma) who were treated with REVLIMID and dexamethasone therapy. Monitor for and advise patients ab...
Learn about multiple myeloma treatment options available for patients from Bristol Myers Squibb®. Please see Indication and Important Safety Information including Boxed WARNINGS.
Thomas Martin, MD:Let’s talk about relapsed and refractory myeloma. When somebody has evidence of relapse, what do you look at to try to help you decide what treatment to give? Yvonne Efebera, MD:The cytogenetics. I try to do a bone marrow biopsy. How long from the initial transplant...
In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma. Image credit: freshidea | stock.adobe.com During a presentation at the National Comprehensive Cancer Network Annual 2024 Conference in Orlando, ...
Multiple myeloma, also known as Kahler's disease, is a type of blood cancer. There's no cure, but treatments can slow its spread and sometimes make symptoms go away. A type of white blood cell called a plasma cell makes antibodies that fight infections in your body. When you have multi...
The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
Pharmacist’s Role in Patient Education and Support: Pharmacists have an important role when providing patients with clear and accessible information about their multiple myeloma diagnosis and treatment options. They can offer tools to help patients manage their medication schedules, regularly check in wi...
Myeloma is a cancer of the plasma cells of the blood. Symptoms include early osteoporosis, hypercalcemia, hyperviscosity of the blood, low red and white blood cell counts, low platelet count, cryoglobulinemia, and amyloidosis. Tests to diagnose multiple
Targeted Oncology: What treatment options have shown the best responses and progression-free survival (PFS) for patients with myeloma? ANDREW YEE, MD:I think the carfilzomib [Kyprolis] options tend to have the best responses and the best progression-free survival [PFS]. I remember when I first...